FDA rejects Yondelis-Doxil combo for ovarian cancer

The FDA has rejected Centecor Ortho Biotech's application to market Doxil in combination with Zeltia's Yondelis (trabectedin) as a treatment for ovarian cancer. Following a panel recommendation issued in July, the agency said it will need more data on overall survival from a Phase III trial already underway, as well as additional pharmacology studies.

The Johnson & Johnson subsidiary said it will review the agency's questions as quickly as possible. "We have full confidence in the product, and (believe) that Johnson will provide the additional information," a Zeltia spokeswoman told the Wall Street Journal.

The expert panel convened in July rejected the Yondelis-Doxil combo due to the heart and liver toxicity risks and the limited effectiveness of the combination. Clinical data showed that the drug only delayed disease progressin by six weeks--a benefit not worth the added risks, the panel concluded.

- here's the Centecor release

Suggested Articles

Gilead is tapping long-term Stanford University researcher Mark Genovese, M.D., to lead its NASH, fibrosis and arthritis pipeline programs.

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.